Chemogenetic activation of the mPFC alleviates impaired fear memory extinction in an animal model of PTSD

Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jun 8:108:110090. doi: 10.1016/j.pnpbp.2020.110090. Epub 2020 Sep 4.

Abstract

Background and aim: Although impaired extinction of fear memory (EFM) is a hallmark symptom of posttraumatic stress disorder (PTSD), the mechanisms underlying the impairment are unknown. Activation of the infralimbic cortex (IL) in the medial prefrontal cortex (mPFC) has been reported to predict successful fear extinction, whereas functionally disrupting this region impairs extinction. We examined whether chemogenetic activation of the IL could alleviate impaired EFM in a single prolonged stress (SPS) rat model of PTSD.

Methods: Chemogenetic activation of IL and prelimbic (PL) excitatory neurons was undertaken to evaluate EFM using a contextual fear conditioning paradigm. Neuronal activity in the IL was recorded using a 32-multichannel silicon electrode. To examine histological changes in the mPFC, apoptosis was measured by TUNEL staining.

Results: Chemogenetic activation of excitatory neurons in the IL, but not the PL, enhanced EFM in sham rats and resulted in alleviation of EFM impairment in SPS rats. The alleviation of impaired EFM in SPS rats was observed during the extinction test session. Neuronal activity in the IL of SPS rats was lower than that of sham rats after clozapine-n-oxide administration. Increased apoptosis was found in the IL of SPS rats.

Conclusions: These findings suggest that a decreased excitatory response in the IL due, at least in part, to an increase in apoptosis in SPS rats leads to impaired EFM, and that neuronal activation during extinction training could be useful for the treatment of impaired EFM in PTSD patients.

Keywords: Animal model of PTSD; Chemogenetic activation; Fear memory extinction; Medial prefrontal cortex; Post-traumatic stress disorder (PTSD).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antipsychotic Agents / administration & dosage
  • Clozapine / administration & dosage
  • Clozapine / analogs & derivatives
  • Disease Models, Animal
  • Extinction, Psychological / drug effects
  • Extinction, Psychological / physiology*
  • Fear / drug effects
  • Fear / physiology*
  • Fear / psychology
  • Genetic Vectors / administration & dosage
  • Male
  • Memory / drug effects
  • Memory / physiology*
  • Piperazines / administration & dosage
  • Prefrontal Cortex / drug effects
  • Prefrontal Cortex / metabolism*
  • Rats
  • Rats, Sprague-Dawley
  • Stress Disorders, Post-Traumatic / genetics*
  • Stress Disorders, Post-Traumatic / metabolism*
  • Stress Disorders, Post-Traumatic / psychology

Substances

  • Antipsychotic Agents
  • DREADD agonist compound 21
  • Piperazines
  • Clozapine
  • clozapine N-oxide